Welcome!

News Feed Item

Novel Alzheimer's Therapeutics Developer Says Investors Should Remain Undeterred Despite Disappointing Results From Major Phase 3 Trials

LOS ANGELES, CA -- (Marketwire) -- 01/30/13 -- During his distinguished career, Dr. Daniel G. Chain, Ph.D. discovered various novel therapeutics to treat Alzheimer's disease which were licensed to multiple Big Pharma giants.

Dr. Chain trained as a Post-doctoral Research Fellow at the Center for Neurobiology and Behavior at Columbia University in New York. Dr. Chain obtained his B.Sc. in Biochemistry from the Institute of Biology in London and obtained his Ph.D. in Biochemistry from the Weizmann Institute of Science in Israel.

He currently serves as Chairman of Intellect Neurosciences, Inc. (OTCQB: ILNS), where he has also been Chief Executive Officer since October 2005.

In an exclusive interview with BioMedReports, Chain says that biotech investors should remain undeterred by the challenges currently being faced by those trying to find a cure for Alzheimer's disease and other age-related cognitive impairments.

BioMedReports: How would you characterize the mood among Alzheimer's researchers after the phase 3 results for Bapineuzumab and Solanezumab?

Dr. Daniel G. Chain, Ph.D.: Obviously, people were very disappointed by the results from the two sets of major Alzheimer's Phase 3 trials, but there were also glimmers of light that renewed hope and even strengthened the prevailing belief that beta amyloid (Aβ) plays a central and causative role in the pathogenesis of Alzheimer's disease. Few now doubt that immunotherapy represents a realistic path forward pending improvements in drug design and the way we conduct clinical trials. Ely Lilly's drug solanezumab showed modest improvement in clinical outcomes when data was pooled from two clinical trials. The drug is to be further tested in a third phase 3 trial by the company and two independent trials conducted by leading academic groups. While bapineuzumab failed to show clinical benefit, the use of biomarkers clearly demonstrated the drug had engaged the target, reduced the amount of plaque and slowed neurodegeneration based upon the decrease in the amount of tau protein measured in the cerebral spinal fluid (CSF). Unfortunately, the drug also caused a significant incidence of vasogenic edema and microhemorrhages, especially in patients that carried the APOE4 gene. A Phase 2 trial is ongoing using a subcutaneous formulation that may avoid these side effects. There is a feeling of optimism among researchers that next generation drugs will have an improved probability of success because of the lessons we have learned from these results and other important recent developments in the field. I experienced this first-hand when I was invited as a Distinguished Speaker to the 6th Annual Alzheimer's Drug Discovery Summit in December and had the opportunity to listen to foremost leaders in the field including academic researchers and industry experts.

Among the themes that have become prevalent is that there is a compelling case for early intervention in the treatment of the disease in which relevant biochemical and neuropathological changes in the brain start many years -- in some case two decades or more -- before symptoms occur! Moreover, the rate of change is far greater before the appearance of symptoms such that the stage we commonly refer to as "Mild," is in fact relatively far advanced, reflecting significant damage to the brain, which is probably beyond repair.

Q: What are the main areas of progress in Alzheimer's research?

Dr. Daniel G. Chain: The development of sensitive brain imaging techniques such as structural MRI to measure brain atrophy, FDG-PET to measure glucose metabolism, and PET amyloid imaging agents represent some of the most important recent advances in the field laying the foundation for studies such as by the Alzheimer's Disease Neuroimaging Initiative (ADNI) and Dominantly Inherited Alzheimer's Network (DIAN) that provided extremely valuable information regarding the sequence of changes preceding and leading to AD. In fact, these studies led to a new way to think about the disease in which presymptomatic AD is just as much a disease state as symptomatic disease.

Q: Describe the main programs at Intellect Neurosciences.

Dr. Daniel G. Chain: Intellect has four main programs underway at the moment: CONJUMAB-A, TAUC3, TOC-1 and RVO3.

We are pioneering the use of antibody-drug conjugates and bi-specific vaccines for the treatment and prevention of multifactorial neurodegenerative conditions such as Alzheimer's disease, Huntington's disease and age-related macular degeneration. Increasingly we hear researchers emphasizing the need to target more than one disease component where, for example, Aβ, tau protein and oxidative stress act in concert and synergistically causing irreversible damage to nerve cells. The use of combination therapies may even allow intervention after symptoms have begun in contrast to monotherapies, targeting only Aβ, for example. However, regulators are averse to the idea of combining two independent investigational drugs before testing each one singly in human clinical trials and demonstrating clinical benefit. That issue is circumvented by the use of antibody drug conjugates in which two different molecules are combined chemically into a single entity as is the case with our CONJUMAB platform.

I am excited about the therapeutic potential of CONJUMAB-A, our lead preclinical program which I believe offers important advantages to other Aβ antibodies currently in clinical development. All the other antibodies e.g. solanezumab, bapineuzumab, gantenerumab and crenzeumab are designed for a single purpose, namely to clear Aβ from the brain. None of these antibodies act on secondary neurotoxic mechanisms such as oxidative stress which causes most of the damage from Aβ. By contrast, CONJUMAB-A, an antibody drug conjugate, is empowered with additional neuroprotective properties to alleviate the damage while also potentially enhancing the clearance of Aβ. In principle our approach could be applied to improve many different types of antibodies including those that previously disappointed in clinical trials. However, we are currently focused on optimizing CONJUMAB-A using our own antibody IN-N01 which targets the N-terminus of Aβ. We believe IN-N01 to be superior to bapineuzumab because of its reduced potential to cause inflammation which results from our reengineering of the originally produced IG1 class antibody into an IgG4 class antibody. We believe this safety feature is particularly important for antibodies that bind Aβ aggregates and not just soluble single monomeric Aβ. Among several potential indications, we have decided to focus on age related macular degeneration (AMD) for proof of concept studies since AMD and AD share several similarities while the eye offers less challenge for delivering the drug.

Over the past two years, Intellect has established its position as a leader in tau immunotherapy using funds from our deal with ViroPharma to support new patent filings by the company, in-license new technologies and initiate an important collaboration with leading Alzheimer's research groups led by Dr. Frank LaFerla and Dr. Kim Green at the University of California, Irvine. Tau immunotherapy is rapidly gaining traction in the Alzheimer's field and has potential applications for many orphan indications as well, such as frontotemporal dementia. However, in contrast to other approaches that have targeted tangles, Intellect is targeting the earliest steps in tau pathology focused on two different pathogenic forms, a truncated form known as delta tau and an aggregated from known as oligomeric tau -- each of which occurs before filaments leading to tangle formation. Over the next several months we expect to generate important in vivo data in relation to the two monoclonal antibodies, TauC3 and TOC-1, that we acquired from Northwestern University under an exclusive license agreement.

Finally, we continue our development of our RECALL-VAX platform focusing on a bi-specific chimeric peptide vaccine approach that targets both Aβ and delta tau in a flu-shot like vaccine approach. Vaccines against multiple antigens have precedent so this is another approach for combination therapies. Disease-modification itself is becoming less attractive as an approach for treating Alzheimer's disease for two main reasons. First, as evidenced by the Phase 3 clinical trials results, patients who are symptomatic probably have disease that is too far advanced to benefit significantly from treatments that slow the degenerative process. Second, treating very early stage or presymptomatic patients will be extremely expensive and prove too costly a burden for healthcare systems. An article by scientists from the Karolinska Institute in Sweden, published in the October issue of Current Alzheimer's Research, indicated the economic cost of treatment with a chronically and frequently administered disease-modifying drug would outweigh the cost of palliative care, including full-time nursing care of patients with advanced disease. This economic model leads one to conclude that a vaccination given on an annual or semi-annual basis may be the only economically feasible approach to prevent and manage Alzheimer's disease. Therefore, a vaccine such as RV03 being developed by Intellect Neurosciences offers a promising prophylactic approach that could potentially be administered to tens of millions of people around the world. Although still at an early stage, we are confident about our ability to produce a high value asset.

Q: Do you feel confident regarding Intellect's pipeline?

Dr. Daniel G. Chain: We are very confident in the science behind our pipeline, and are encouraged by the interest shown in our programs by several global pharmaceutical companies some of which have already signed confidentiality agreements. In addition, many independent papers have been published recently that support many of our hypotheses for the development of these assets. Further, we are beginning to see encouraging early stage results that we hope to share soon regarding each of our pipeline programs.

Q: What challenges do you face?

Dr. Daniel G. Chain: The biggest challenge is the funding needed to support our R&D activities and also to grow and maintain our substantial global patent portfolio, which is the heart of Intellect's business model. We need to dispel the skepticism that pervades among many stakeholders in the pharmaceutical industry resulting from previous disappointments in the AD field, or at least separate ourselves from it.

One of Intellect's strengths is its diversified portfolio, which provides us "multiple shots on goal." We are extremely cost-efficient as the result of effective outsourcing R&D to highly specialized contract research organizations. Even so, as a small company, maintaining adequate funding to continue all of our programs concurrently is quite challenging. We are currently in talks with potential licensing and co-marketing partners to help maintain the pace of our research, but in this environment, we are facing the same challenges as all other companies of our relative size. We, therefore, have to choose which programs to push forward at any given moment, which often disrupts the momentum of other programs, all based upon the funding we receive and the goals of potential partners who continue nevertheless to show considerable interest and have expressed an eagerness to see validation in preclinical models.

Q: Do you have anything you wish to add?

Dr. Daniel G. Chain: It is imperative that the company and its investors remain undeterred by the challenges currently being faced both by the industry and within Intellect itself. Intellect has continued to grow and develop new strategies to continue on regardless of what the market has done. We wish to communicate to our current and potential investors that significant advances have been made in the Alzheimer's area and express our confidence in our ability to prevail where others have failed. While one set of compounds for which we hold licenses has met with challenges, that is not the entirety of Intellect Neurosciences. Intellect has never relied solely on one program to sustain it, and we have continuously executed on our plans to license our programs, and anticipate being able to do so again as we generate new data and advance our earlier-stage programs through proof of concept.

The full version of this report can be found here:

http://www.biomedreports.com/20130130120929/novel-therapeutics-developer-says-investors-should-remain-undeterred-despite-resutls-from-major-alzheimers-phase-3-trials.html

Healthcare investors and Biotech traders interested in accessing BioMedReports' new complete database of clinical trials and upcoming FDA and world-wide regulatory decisions which can be used to make more profitable trades and see upcoming catalysts can go to: http://biomedreports.com/fdacal.html

Follow Us

News developments and live healthcare sector updates are available constantly via Twitter at: http://twitter.com/BioMedReports

About BioMedReports.Com

BioMedReports is a news and research portal covering financial biotech news for the entire Healthcare Sector of the market. BioMedReports is not paid or compensated to report the news and developments of publicly traded companies. BioMedReports sells a premium product for subscribers and full disclosures and information about the stocks and news mentioned in this news release are available at BioMedReports.Com

Add to Digg Bookmark with del.icio.us Add to Newsvine

Media Contacts Only:
M. Davila
Assistant Editor
BioMedReports.Com
e-mail: Email Contact

More Stories By Marketwired .

Copyright © 2009 Marketwired. All rights reserved. All the news releases provided by Marketwired are copyrighted. Any forms of copying other than an individual user's personal reference without express written permission is prohibited. Further distribution of these materials is strictly forbidden, including but not limited to, posting, emailing, faxing, archiving in a public database, redistributing via a computer network or in a printed form.

Latest Stories
With major technology companies and startups seriously embracing Cloud strategies, now is the perfect time to attend 21st Cloud Expo October 31 - November 2, 2017, at the Santa Clara Convention Center, CA, and June 12-14, 2018, at the Javits Center in New York City, NY, and learn what is going on, contribute to the discussions, and ensure that your enterprise is on the right path to Digital Transformation.
@DevOpsSummit at Cloud Expo taking place Oct 31 - Nov 2, 2017, at the Santa Clara Convention Center, Santa Clara, CA, is co-located with the 21st International Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is ...
New competitors, disruptive technologies, and growing expectations are pushing every business to both adopt and deliver new digital services. This ‘Digital Transformation’ demands rapid delivery and continuous iteration of new competitive services via multiple channels, which in turn demands new service delivery techniques – including DevOps. In this power panel at @DevOpsSummit 20th Cloud Expo, moderated by DevOps Conference Co-Chair Andi Mann, panelists examined how DevOps helps to meet the de...
Automation is enabling enterprises to design, deploy, and manage more complex, hybrid cloud environments. Yet the people who manage these environments must be trained in and understanding these environments better than ever before. A new era of analytics and cognitive computing is adding intelligence, but also more complexity, to these cloud environments. How smart is your cloud? How smart should it be? In this power panel at 20th Cloud Expo, moderated by Conference Chair Roger Strukhoff, pane...
No hype cycles or predictions of zillions of things here. IoT is big. You get it. You know your business and have great ideas for a business transformation strategy. What comes next? Time to make it happen. In his session at @ThingsExpo, Jay Mason, Associate Partner at M&S Consulting, presented a step-by-step plan to develop your technology implementation strategy. He discussed the evaluation of communication standards and IoT messaging protocols, data analytics considerations, edge-to-cloud tec...
When growing capacity and power in the data center, the architectural trade-offs between server scale-up vs. scale-out continue to be debated. Both approaches are valid: scale-out adds multiple, smaller servers running in a distributed computing model, while scale-up adds fewer, more powerful servers that are capable of running larger workloads. It’s worth noting that there are additional, unique advantages that scale-up architectures offer. One big advantage is large memory and compute capacity...
In 2014, Amazon announced a new form of compute called Lambda. We didn't know it at the time, but this represented a fundamental shift in what we expect from cloud computing. Now, all of the major cloud computing vendors want to take part in this disruptive technology. In his session at 20th Cloud Expo, Doug Vanderweide, an instructor at Linux Academy, discussed why major players like AWS, Microsoft Azure, IBM Bluemix, and Google Cloud Platform are all trying to sidestep VMs and containers wit...
What's the role of an IT self-service portal when you get to continuous delivery and Infrastructure as Code? This general session showed how to create the continuous delivery culture and eight accelerators for leading the change. Don Demcsak is a DevOps and Cloud Native Modernization Principal for Dell EMC based out of New Jersey. He is a former, long time, Microsoft Most Valuable Professional, specializing in building and architecting Application Delivery Pipelines for hybrid legacy, and cloud ...
Amazon started as an online bookseller 20 years ago. Since then, it has evolved into a technology juggernaut that has disrupted multiple markets and industries and touches many aspects of our lives. It is a relentless technology and business model innovator driving disruption throughout numerous ecosystems. Amazon’s AWS revenues alone are approaching $16B a year making it one of the largest IT companies in the world. With dominant offerings in Cloud, IoT, eCommerce, Big Data, AI, Digital Assista...
SYS-CON Events announced today that CA Technologies has been named "Platinum Sponsor" of SYS-CON's 21st International Cloud Expo®, which will take place October 31-November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA. CA Technologies helps customers succeed in a future where every business - from apparel to energy - is being rewritten by software. From planning to development to management to security, CA creates software that fuels transformation for companies in the applic...
Artificial intelligence, machine learning, neural networks. We’re in the midst of a wave of excitement around AI such as hasn’t been seen for a few decades. But those previous periods of inflated expectations led to troughs of disappointment. Will this time be different? Most likely. Applications of AI such as predictive analytics are already decreasing costs and improving reliability of industrial machinery. Furthermore, the funding and research going into AI now comes from a wide range of com...
Multiple data types are pouring into IoT deployments. Data is coming in small packages as well as enormous files and data streams of many sizes. Widespread use of mobile devices adds to the total. In this power panel at @ThingsExpo, moderated by Conference Chair Roger Strukhoff, panelists looked at the tools and environments that are being put to use in IoT deployments, as well as the team skills a modern enterprise IT shop needs to keep things running, get a handle on all this data, and deliver...
Internet of @ThingsExpo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The Internet of Things (IoT) is the most profound change in personal and enterprise IT since the creation of the Worldwide Web more than 20 years ago. All major researchers estimate there will be tens of billions devic...
DevOps at Cloud Expo, taking place October 31 - November 2, 2017, at the Santa Clara Convention Center in Santa Clara, CA, is co-located with 21st Cloud Expo and will feature technical sessions from a rock star conference faculty and the leading industry players in the world. The widespread success of cloud computing is driving the DevOps revolution in enterprise IT. Now as never before, development teams must communicate and collaborate in a dynamic, 24/7/365 environment. There is no time to w...
For organizations that have amassed large sums of software complexity, taking a microservices approach is the first step toward DevOps and continuous improvement / development. Integrating system-level analysis with microservices makes it easier to change and add functionality to applications at any time without the increase of risk. Before you start big transformation projects or a cloud migration, make sure these changes won’t take down your entire organization.